In a significant boost to the nation's poultry industry, Boehringer Ingelheim has announced the launch of its innovative trivalent vaccine, VAXXITEK® HVT+IBD+H5, scheduled for February 2025. The new vaccine promises comprehensive protection against three of the most critical diseases affecting poultry: Marek's disease, Infectious Bursal Disease (Gumboro), and H5 avian influenza. Developed to address the heavy impact of H5 avian influenza—a highly contagious and notifiable zoonotic disease that has disrupted global poultry production and trade—the vaccine is designed for administration at the hatchery. This early intervention secures vital protection for chicks, effectively bridging the immunity gap between the waning maternal antibodies and the onset of active immunity. Marek's disease, a viral condition that can cause tumors, paralysis, and high mortality rates, and Infectious Bursal Disease, known for inducing severe dehydration and productivity losses, have long challenged poultry producers worldwide. Vaccination against these diseases is already standard practice. However, the introduction of VAXXITEK® HVT+IBD+H5 marks the first instance globally where protection against H5 avian influenza is integrated into a single shot with these other critical vaccines. Boehringer Ingelheim's breakthrough is underpinned by its COBRA (Computationally Optimised Broadly Reactive Antigen) technology, which has enabled the development of a unique antigen sequence. This innovation not only broadens the vaccine's coverage against multiple H5 avian influenza clades but also enhances its overall efficacy. "The launch of VAXXITEK® HVT+IBD+H5 is another step forward in avian influenza prevention regarding both coverage and convenience," said Taoufik Rawi, Head of Franchise, Poultry at Boehringer Ingelheim. "Our customers must keep their flocks thriving and protect their chickens from health threats. With this three-in-one vaccine, we offer a quick and effective solution against the most prevalent H5 clades and two major poultry diseases." The vaccine's DIVA (Differentiating Infected from Vaccinated Animals) capability is a crucial feature, allowing authorities to distinguish between vaccinated and naturally infected birds—a vital tool in managing disease outbreaks. Dr. David Swayne, former Laboratory Director at the USDA and Adjunct Professor at the University of Georgia, USA, noted, "The evolution of H5 avian influenza continues to pose a significant challenge for poultry health worldwide. Advancements in disease management strategies, including vaccination, play a crucial role in helping protect poultry flocks from its impact." Regional impact was underscored by industry leaders. Waleed El Mashak, Head of Animal Health IMETA at Boehringer Ingelheim, emphasized, "As a region heavily impacted by avian influenza, the launch of VAXXITEK® HVT+IBD+H5 represents a critical advancement for poultry farmers across IMETA. Launching this vaccine in Egypt for the first time globally is a testament to our commitment to supporting sustainable poultry farming." Magdy Hassan, President of the Egyptian Veterinary Syndicate, described the introduction of the vaccine as "a significant milestone, offering poultry farmers a powerful solution to enhance flock immunity and protect against major diseases, including H5 avian influenza." Mahmoud El Mahdy, Country Head of Animal Health for North, East, and West Africa at Boehringer Ingelheim, added, "This innovative vaccine is a game-changing approach to disease control, bolstering market stability and securing international trade opportunities. It underscores our ongoing commitment to advancing sustainable food production in Egypt." As Egypt's poultry sector continues to play a crucial role in the country's food security and economy, the launch of VAXXITEK® HVT+IBD+H5 is expected to deliver significant benefits for both producers and consumers, heralding a new era of enhanced disease control and sustainable poultry production.
